middle.news
Dimerix Completes Recruitment in Pivotal Phase 3 Trial for Rare Kidney Disease
8:54am on Monday 15th of December, 2025 AEDT
•
Healthcare
Read Story
Dimerix Completes Recruitment in Pivotal Phase 3 Trial for Rare Kidney Disease
8:54am on Monday 15th of December, 2025 AEDT
Key Points
Completed recruitment and dosing of 286 adult patients in ACTION3 Phase 3 trial
Positive interim results showing DMX-200 reduces proteinuria in FSGS patients
94% of eligible patients entered Open Label Extension study
Ongoing pediatric recruitment as an independent cohort
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE